Adicet Bio Inc

Research Adicet Bio Inc (1IJ) on Bullrun: market cap EUR 65.91M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker1IJ
• ExchangeF
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 65.91M

Valuation Snapshot

latest market cap is EUR 65.91M.

About Adicet Bio Inc

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen.

Frequently asked questions

What is Adicet Bio Inc's market cap?

Adicet Bio Inc's market capitalization is EUR 65.91M.

What does Adicet Bio Inc do?

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States.